Intertek Launches Comprehensive Inhalation Product Development Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Intertek Launches Comprehensive Inhalation Product Development Services


Intertek announced that it is now offering comprehensive services for the development of orally inhaled and intranasal drug products (OINDPs) for both small molecules and biologics. This follows the company’s acquisition of Melbourn Scientific.

The services include formulation, analytical method development and validation, drug product physical characterization, chemistry, manufacturing and controls (CMC) support, stability studies and QC release testing. The company can also provide regulatory affairs consultancy, bioanalysis and extractables and leachables (E&Ls) studies for all types of inhalation medicine products.

There is an increasing demand for more user-friendly drug delivery products, such as OINDP, which can offer improved patient outcomes. The development of these products requires specialist capabilities and test facilities for techniques such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI), spray pattern/plume geometry and delivered dose assessment.

A key challenge in OINDP development is the control of E&Ls. With inhalation products that deliver the drug directly to the lungs, the rubber and plastic inhaler device components are in constant contact with the product formulation. Consequently, there is a potential for substances to leach from the device components into the drug product. Intertek can provide E&L studies supporting OINDP development.

Source: Intertek

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here